Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.
about
Novel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten CarrierViraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trialVaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches.Improvement of cytomegalovirus pp65 DNA vaccine efficacy by co-administration of siRNAs targeting BAK and BAXEnhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909)Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases.Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironmentCMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.Priorities for CMV vaccine developmentThe immune response to human CMVCytomegalovirus pneumonia in hematopoietic stem cell recipients.A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis.T cell responses to viral infections - opportunities for Peptide vaccination.Cytomegalovirus pp65 limits dissemination but is dispensable for persistence.Cytomegalovirus vaccine: phase II clinical trial results.Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation.The history of vaccination against cytomegalovirus.Cytomegalovirus Vaccines: Current Status and Future Prospects.Design of cocktail peptide vaccine against Cytomegalovirus infection.MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.Suppression of cytomegalovirus-specific CD8(+)T cells by everolimus.Cytomegalovirus vaccines under clinical developmentIs HCMV vaccine an unmet need? The state of art of vaccine development.Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.Advancing our understanding of protective maternal immunity as a guide for development of vaccines to reduce congenital cytomegalovirus infections.Linear and branched polyacrylates as a delivery platform for peptide-based vaccines.Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation
P2860
Q28542642-4CDAD4EA-0922-4497-87E4-796F221E98AFQ33429827-E2E7D05F-AE80-4C3D-8724-E9C028F954CEQ33723534-829C7C8F-4E56-460D-AC32-E94215D9326EQ33734872-90DCD4A0-F208-46E2-BE9C-1E85089ED9DEQ33744024-216A3A49-31FA-455E-8C69-B07A31F47D83Q34047191-59008E29-7ACC-4EF5-8814-A1CEAD2670A6Q34349745-BC1D97FC-AC94-4859-9E15-0AC8FFE9CED5Q34613585-A765797D-9E79-47D4-AA3B-C299CDD45AC8Q34757847-0FCDBD8C-1BA7-4306-9C7C-E382332F8A30Q35811921-317C08D7-E82C-4175-A58E-17287A7DDED8Q36216553-91B6B696-AA12-46B0-8CF7-F52E6701B274Q36517022-EE8C3B9E-6E82-4E99-8E52-BAA3EBCAF5B7Q37179131-78AE52DA-CAE1-44B2-80E7-C2CE9F390972Q37272354-914186F9-BA64-4C3B-B95E-7784EA3E8BB7Q37718978-52818DAF-8732-4FBD-A190-D98786953CD6Q37728492-99B9C3B7-AD8F-436A-B0A1-9571A4954CDEQ38166861-5102B20F-9B4E-4BFD-B60F-CBE8824E6CFEQ38281851-EA86242E-93DF-4101-B827-6CC5471DF6BAQ38384533-A6BE12A6-03E4-46AE-992D-AF186EE704CDQ38791353-2631F84D-A734-4D8E-A80A-AEA3A9038561Q38859818-E85ED36E-3884-42DE-8624-BAD45F16A243Q40497816-6478DD77-A923-4169-9551-5C5BC5978D8FQ42284856-7E9035A6-095D-4C75-A612-A663680F0F83Q42380888-90D53ABD-910C-41DC-9510-B61F3D6A0FA7Q43467283-0F59D6A9-989B-4AC4-B8F8-F13B2836C54EQ47115255-88F40E9C-7741-46C8-970E-B7E3B0F53BDDQ47546281-A78C247B-48E5-4818-9083-0F9E91330ED1Q51539386-7A7A24C2-11D2-49A7-8576-6124CF9F9651Q57053200-1CCAE8DE-12E4-433B-B2A1-D2ABB1FF4AA8
P2860
Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Clinical evaluation of safety ...... r without PF03512676 adjuvant.
@ast
Clinical evaluation of safety ...... r without PF03512676 adjuvant.
@en
type
label
Clinical evaluation of safety ...... r without PF03512676 adjuvant.
@ast
Clinical evaluation of safety ...... r without PF03512676 adjuvant.
@en
prefLabel
Clinical evaluation of safety ...... r without PF03512676 adjuvant.
@ast
Clinical evaluation of safety ...... r without PF03512676 adjuvant.
@en
P2093
P2860
P356
P1476
Clinical evaluation of safety ...... r without PF03512676 adjuvant.
@en
P2093
Arthur M Krieg
Brenda Williams
Corinna La Rosa
Denise Marsano
Jennifer Drake
John A Zaia
Larry Couture
Morris I Kelsey
Peter Kwon
Rahul Sharan
P2860
P304
P356
10.1093/INFDIS/JIS107
P407
P577
2012-03-07T00:00:00Z